Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

446
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
446

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Packed red blood cell transfusion affecting phosphatidylethanol concentration.

Clinical toxicology (Philadelphia, Pa.)·2026
Same author

Meeting the Operational Needs of Clinical Laboratories around the World.

The journal of applied laboratory medicine·2026
Same author

ADLM Guidance Document on Laboratory Testing for Drugs of Misuse to Support the Emergency Department.

The journal of applied laboratory medicine·2026
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Developing Topics.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Improvements, Challenges, and the Investigation of Two Unknowns in Arsenic Urine Speciation Analysis by HPLC-ICP-MS: From Development to Post-implementation.

Therapeutic drug monitoring·2025
Same journal

Is drug facilitated sexual assault changing? About a case involving 4-bromomethcathinone.

Journal of analytical toxicology·2026
Same journal

Differentiation of 2-, 3-, and 4-Fluorofuranylfentanyl Using HPLC-MS and Human Liver Microsomes.

Journal of analytical toxicology·2026
Same journal

Trends and Circumstances of Pediatric Fentanyl Deaths in North Carolina: A 10-year Retrospective Study.

Journal of analytical toxicology·2026
Same journal

Drug Detection in Traffic-Related Fatalities in Connecticut (2020-2024).

Journal of analytical toxicology·2026
Same journal

Characterization of postmortem γ-hydroxybutyric acid (GHB) and a novel model to discern exogenous use.

Journal of analytical toxicology·2026
Same journal

Development and validation of a quantitative analytical method for urine samples in drug-facilitated sexual assault cases.

Journal of analytical toxicology·2026
See all related articles

Related Experiment Video

Updated: Sep 17, 2025

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.8K

Immunalysis tapentadol assay reformulation resolves tramadol interference.

Adeolu O Adegoke1,2, Alexandria N Jackson3,2, Sonia L La'ulu3,2

  • 1Department of Pathology, University of Utah Health, Salt Lake City, UT 84132, United States.

Journal of Analytical Toxicology
|June 30, 2025
PubMed
Summary
This summary is machine-generated.

A new urine screening kit significantly reduces false-positive tapentadol results caused by tramadol cross-reactivity. This improved assay enhances accuracy in monitoring pain management medications.

More Related Videos

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
10:13

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

2.4K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.0K

Related Experiment Videos

Last Updated: Sep 17, 2025

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.8K
Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
10:13

Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs

Published on: November 8, 2024

2.4K
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.0K

Area of Science:

  • Clinical Chemistry
  • Forensic Toxicology
  • Pharmacology

Background:

  • Tapentadol and tramadol are structurally related analgesics with overlapping mechanisms of action.
  • Cross-reactivity in immunoassays can lead to inaccurate urine drug screening results, complicating patient monitoring.
  • The Immunalysis Tapentadol 343 Urine Enzyme Immunoassay (EIA) kit has shown potential for false-positive results due to tramadol.

Purpose of the Study:

  • To evaluate the specificity of the Immunalysis Tapentadol 343 Urine EIA kit regarding tramadol cross-reactivity.
  • To assess the performance of a reformulated Immunalysis Tapentadol 343UR Urine HEIA kit in detecting tapentadol accurately.
  • To determine the impact of assay improvements on reducing false-positive screening results in clinical practice.

Main Methods:

  • Initial screening of 28 urine samples using the original Immunalysis Tapentadol 343 Urine EIA kit.
  • Confirmation of tapentadol absence in false-positive samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
  • Retesting of samples with the reformulated Immunalysis Tapentadol 343UR Urine HEIA kit to assess improved specificity.

Main Results:

  • The original EIA kit produced 28 false-positive results for tapentadol.
  • Liquid chromatography-tandem mass spectrometry (LC-MS/MS) confirmed the absence of tapentadol in these samples.
  • Sixty-one percent of false-positive samples contained tramadol below the manufacturer's stated threshold.
  • The reformulated Immunalysis Tapentadol 343UR kit successfully eliminated false-positive results for tapentadol in the evaluated samples.

Conclusions:

  • The original Immunalysis Tapentadol 343 Urine EIA kit exhibits significant cross-reactivity with tramadol, leading to false-positive tapentadol results.
  • The reformulated Immunalysis Tapentadol 343UR Urine HEIA kit demonstrates improved specificity and accuracy for tapentadol detection.
  • Assay verification and the use of improved kits are crucial for accurate drug monitoring in pain management and forensic toxicology.